Ekso Bionics Holdings, Inc. Common Stock Q4 FY2024 Earnings Call
· Earnings call transcript and AI-powered summary
Prepared remarks from CEO Scott Davis, CFO Jerome Wong, and COO Jason Jones. Focus on record Q4 revenue, gross margin expansion, cost discipline, and scaling the Ekso Indigo Personal go-to-market strategy via CMS reimbursement and new distribution partnerships.
Financial Highlights – Q4 2024 vs. Q4 2023
- Revenue: $5.1 million (+5% YoY from $4.8 million) – record quarterly revenue.
- Gross Profit & Margin: $2.7 million at 53% margin (vs. $2.4 million at 49% margin) – improvement driven by supply chain efficiencies and lower service costs.
- Operating Expenses: $4.9 million (-15% YoY from $5.8 million) – reduced headcount, discretionary payroll, and consulting costs.
- Net Loss: $3.4 million ($0.14 per basic/diluted share) vs. $3.2 million ($0.22 per share).
- Cash Used in Operations: $1.4 million (vs. $1.6 million).
Financial Highlights – Full Year 2024 vs. Full Year 2023
- Revenue: $17.9 million (vs. $18.3 million) – marginal decline attributed to 2023 procurement cycles with large IDNs and delivery of ~$2M VA pipeline inherited from the 2022 Parker Hannifin acquisition; 2024 focused on rebuilding that pipeline.
Continue Reading
Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.
Upgrade to ProfessionalContinue Reading
Unlock the full earnings call transcript with speaker labels and formatted dialogue.
Upgrade to Professional